CRINETICS PHARMACEUTICALS INC. - COMMON STOCK

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

12 Jul 2022 17:09:22 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10 Jun 2022 16:30:47 By Nasdaq GlobeNewswire

Crinetics Presents Clinical and Research Results at ENDO 2022

08 Jun 2022 07:30:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals to Participate in the JMP Securities Life Sciences Conference

07 Jun 2022 07:30:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Reports Positive Top-line Results Including Strong Adrenal Suppression from CRN04894 Phase 1 Study Multiple-Ascending Dose Cohorts

25 May 2022 07:00:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

12 May 2022 16:41:57 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10 May 2022 16:18:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces Closing of Underwritten Common Stock Offering

18 Apr 2022 16:01:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces Pricing of Underwritten Common Stock Offering

12 Apr 2022 23:52:43 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

11 Apr 2022 17:15:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results

30 Mar 2022 16:02:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Reports Positive Top-Line Results from CRN04777 Phase 1 Study Multiple-Ascending Dose Cohorts

30 Mar 2022 16:01:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Appoints Chris Robillard as Chief Business Officer

21 Mar 2022 07:30:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10 Mar 2022 17:20:34 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Expands Executive Team with Appointment of James Hassard as Chief Commercial Officer

01 Mar 2022 08:00:18 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals and Sanwa Kagaku Kenkyusho Enter into Exclusive Licensing Agreement for the Development and Commercialization of Paltusotine in Japan

28 Feb 2022 06:00:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals to Participate in SVB Leerink Global Healthcare Conference

09 Feb 2022 07:30:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 Feb 2022 16:42:26 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals to Present Corporate and Clinical Update at 40th Annual J.P. Morgan Healthcare Conference

12 Jan 2022 07:30:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Adds Board Member with Global Rare Disease Expertise with Appointment of Rogério Vivaldi Coelho, M.D., M.B.A.

05 Jan 2022 07:30:00 By Nasdaq GlobeNewswire